



Olink® Reveal

Proteomics, Unplugged


Powerful NGS-based proteomics—
effortlessly uncover meaningful insights

Unlimited insights, Untapped potential

Genomics + Proteomics: The Ultimate Partnership for Discovery

Proteomics takes the success of genomics further, offering dynamic, real-time insights into human biology and its changes—key for advancing precision medicine.

Proteins bridge the gap between genotype and phenotype, while responding to the environment.



Unlocking the Power of Proteomics at Scale

Olink has been chosen to analyze 600,000 samples in the UK Biobank (UKB) Pharma Proteomics Project, the world's largest human proteogenomics study.

"To date, the scientific community has invested substantially in genomics for the advancement of precision medicine. However, to identify the right drug for the right patient at the right time, we must move beyond genomics alone. This dataset will help paint a much more nuanced and detailed picture of how the human genome and proteins circulating in the blood influence human health and disease – enabling biomedical researchers to identify new biological associations, find new drug targets and build blood-based diagnostics."

Dr Chris Whelan, Director, Neuroscience, Data Science & Digital Health, Janssen Research & Development, LLC, a Johnson & Johnson Company, Pharma Proteomics Project Lead.²

1 - <https://www.nature.com/articles/s41586-023-06592-6>

2 - <https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news>

UKB Pilot Outcomes¹

Identified pathways
for drug targets

Improved disease
prediction scores

>14,000 protein
QTLs identified

100s peer
reviewed studies


“As a genomics lab, it's important to leverage NGS-based proteomics, using a method that can work across a wide range of sample matrices with tools we already have in the lab.”

Professor Chris Mason, Weill Cornell Medicine, NY

Welcome to Proteomics, Unplugged


Olink Reveal: Accessible NGS-based Proteomics

High-plex protein analysis, made accessible, flexible, and cost-effective.



Simplified Workflow

- Seamlessly integrated with NGS
- Efficient library prep with standard lab techniques



Powerful Content


- Broad proteome coverage
- Deep profiling of inflammation processes



Accessible Solution

- Affordable library prep
- Access to proprietary data analysis tools

Olink Reveal Library Prep



Easy library prep protocol seamlessly integrates with NGS workflow

- Dilute samples, incubate, PCR
- 2.5 hours hands on time

NGS readout



Works with a range of mid- and high-throughput sequencers

- NextSeq 2000 • NovaSeq X
- NovaSeq 6000 • and more

Analysis




Comprehensive software tools for all knowledge levels

- QC raw data
- Data analysis and visualization

“It was easy to implement the Olink protocol and send libraries off for sequencing, getting useful results from the first sample cohorts.”

Dr. Magnus Palmblad, Group Leader, Center for Proteomics & Metabolomics,
Leiden University Medical Center

Powerful Content, Actionable Insights



Curated Content That Unlocks New Discoveries

Olink Reveal provides broad proteome coverage and deep profiling of inflammation and immune response.

Broad proteome coverage

100% top level pathways and 64% of all pathways in Reactome¹

1 - reactome.org

Deep profiling of inflammation

537 inflammation proteins covering 96% of immune response pathways in Reactome²

2 - Reactome, Open Targets and Gene Ontology


Curated library

~1,000 proteins, robustly detectable markers, with high proportion of *cis*-pQTLs for proteogenomics associations³

3 - PMID: 37794186, 39316441, 37794188




Olink Reveal covers all major pathways on level 0 and 64% of all levels from 0-12. This remains close to Olink Explore HT coverage, which targets 5 times more proteins.



“The number of proteins and breadth of pathways covered enabled us to identify proteins that may differentiate how leukemia patients respond differently to various BTK inhibitors over time. Due to its affordable cost, it would enable groups to scale testing across a large number of subjects and timepoints.”

Professor Edvard Smith, Karolinska Institute




Volcano plots represent typical results obtained with Olink Reveal with pink markers denoting significant (adjusted $p < 0.05$) and grey markers denoting non-significant

“Olink Reveal enabled us to identify biomarkers relevant for prediabetes that correlate with clinical data in our biobank samples.”

Professor Karol Kaminski, Medical University Bialystok

Accessible Solution, Affordable Results



* reflects estimated per-sample USD cost of Olink® Reveal reagent kit


“Core facilities will be interested in adopting Olink Reveal because there is no need for capex, and it just plugs into the normal genomics workflow.”

Catharine Aquino, Functional Genomics Center Zurich, ETH Zürich

Trusted Technology, Demonstrated Results


PEA Technology: Trusted for Precision and Reliability

Olink Reveal leverages the power of Olink's Proximity Extension Assay (PEA) technology, demonstrated through more than 2,300 publications.



Setting the Standard for Proteomics Validation

Every assay is lab validated by our comprehensive 3-step, 15-factor assay validation process. The Olink Reveal library is enriched for proteins that are genetically validated.





Olink Reveal Performance Specifications

- High Sensitivity: Detects as low as fg/ml
- Broad Compatibility: Validated in plasma and serum; compatible with various other matrices
- High Precision:
 - Intra-plate CVs: 8.1%
 - Inter-plate CVs: 4.8%
 - Inter-site CVs: 6.3%
- Robust Marker Detection: Reliable performance across a wide range of biological markers
- Biological Detectability Range: 86-100%
- NGS Platform Compatibility: Supports multiple platforms, including NovaSeq X, NovaSeq 6000, NextSeq 2000, and more
- Reproducibility: High concordance with other Olink products based on overlapping content (R=0.95 Olink Explore HT, R=0.94 Olink Explore 3072, R=0.90 Olink Target 96 Inflammation) and high concordance between sites (R= 0.96-0.98)

Contact us to start your proteomics journey today with Olink Reveal or any of our other proteomics solutions at www.olink.com/reveal



© 2025 Olink Proteomics AB, part of Thermo Fisher Scientific.

Olink products and services are For Research Use Only. Not for use in diagnostic procedures. All information in this document is subject to change without notice. This document is not intended to convey any warranties, representations and/or recommendations of any kind, unless such warranties, representations and/or recommendations are explicitly stated. Olink assumes no liability arising from a prospective reader's actions based on this document. OLINK, NPX, PEA, PROXIMITY EXTENSION, INSIGHT and the Olink logotype are trademarks registered, or pending registration, by Olink Proteomics AB. All third-party trademarks are the property of their respective owners. Olink products and assay methods are covered by several patents and patent applications <https://www.olink.com/patents/>.

1586, v1.3, 2025-08-12